Related Experiment Video
Updated: Apr 23, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
First report on ototoxicity of meglumine antimoniate
Cláudia Maria Valete-Rosalino1, Maria Helena Araujo-Melo1, Débora Cristina de Oliveira Bezerra2
1Fundação Oswaldo Cruz (IPEC-FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Introduction:
Pentavalent antimonials are the first drug of choice in the treatment of tegumentary leishmaniasis. Data on ototoxicity related with such drugs is scarcely available in literature, leading us to develop a study on cochleovestibular functions.
Case Report:
A case of a tegumentary leishmaniasis patient, a 78-year-old man who presented a substantial increase in auditory threshold with tinnitus and severe rotatory dizziness during the treatment with meglumine antimoniate, is reported. These symptoms worsened in two weeks after treatment was interrupted.
Conclusion:
Dizziness and tinnitus had already been related to meglumine antimoniate. However, this is the first well documented case of cochlear-vestibular toxicity related to meglumine antimoniate.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Antiepileptic Drugs: Glutamate Antagonists

